Founder & CEO, Flagship Pioneering
Search every verified Noubar Afeyan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Noubar Afeyan, chairman of Moderna and founder and CEO of Flagship Pioneering, discussed the company's late-stage trial results for a melanoma vaccine in an August 2026 interview. He described the data as a milestone and compared the moment to the earlier development of a COVID-19 vaccine, calling it a "déjà vu moment." Afeyan said the phase two results, followed for five years, indicated a 45 to 50 percent improvement in risk-free survival and metastasis-free survival when combined with Merck's Keytruda, which he described as an improvement over the current gold standard. He also noted that the COVID-19 pandemic contributed to greater understanding of the immune system, which he said is informing more potent immunotherapies, and he credited artificial intelligence with helping convert data into better-informed decisions. In a July 2026 interview, Afeyan reflected on the origins of Flagship Pioneering, which he said was founded on the idea of creating multiple companies simultaneously, an approach he contrasted with the traditional model of serial entrepreneurship. He stated that the entity, initially called NewcoGen, later became Flagship Ventures and then Flagship Pioneering, and that it has helped launch more than 100 companies, with 30 now publicly traded. Afeyan said Moderna was not conceived as a single company but as one of many potential outcomes, and that "experiments in reality and execution" determined which ideas survived. He also remarked that transformative breakthroughs often come from "unreasonable beginnings" and that focusing only on reasonable ones is unlikely to yield major discoveries.
"It was a déjà vu moment, in the sense that we had a similar moment some roughly six years ago, when the technology was directed in a very different place, which was a COVID-19 vaccine, and we had some pretty exciting data. It really did feel like that." Moderna Chairman Noubar Afeyan on the breakthrough that led to its new melanoma vaccine.
On April 23, 2026, the Aurora Humanitarian Initiative hosted a session titled “Funding a New Humanitarianism: Scaling Global Support for Locally Led Responses” during the Skoll World Forum in Oxford, UK. In his opening remarks, Aurora Co-Founder and Board Chair Noubar Afeyan reflected on Gratitude in Action, common humanity, and what he described as “inhumanitarianism”: the erosion of humanism in the face of growing humanitarian need. He spoke about Aurora’s mission to turn the spark of common humanity into action by recognizing grassroots leaders who are best positioned to respond to challeng…
In this episode of Encounters, we’re delighted to welcome Noubar Afeyan, Founder and CEO of Flagship Pioneering and co-founder of Moderna. Noubar is a pioneering biotechnology entrepreneur and venture creator whose work has helped launch and scale dozens of transformative life sciences companies. Trained as a biochemical engineer, he has spent his career building platforms that bridge science, venture creation, and global health innovation. In our conversation, Noubar reflects on his journey from academia to company creation, the philosophy behind Flagship’s venture-creation model, and the mi…
Dr. Afeyan discusses advancements in healthcare and the impact of AI. He emphasizes the importance of healthcare access and affordability. The discussion highlights scientific megaclusters and the need for investment in both public and private sectors. The speaker describes the rapid vaccine development during the pandemic. He shares his experience in founding biotech companies and the revolutionary potential of AI in drug discovery and patient selection. He suggests a shift from sick care to preemptive health and medicine. The speaker advocates for government regulation and health account…
A forward-looking conversation on how AI is transforming innovation, science, and human progress. From future-backwards thinking and poly-intelligence to medicine, universities, and the scientific method itself, this discussion explores how AI can accelerate discovery, reveal nature’s intelligence, and help society tackle problems once thought too complex to solve.
"There are opinions and assertions, and if you don't have to match facts with facts, at least a comparable volume of it, then it's really hard to figure out what the truth is." Moderna Chairman Noubar Afeyan on biotechnology and science skepticism.
How existential are the current threats to US science? Noubar Afeyan, founder and CEO at Flagship Pioneering, joined us to point out the various landmines dotting the landscape during a live taping of Post-Hoc Live out at the JP Morgan Healthcare Conference.
Flagship Founder and CEO Noubar Afeyan and Stripe Co-Founder and CEO Patrick Collison discuss the ingenuity accelerating ...
“We are in the business officially at Flagship at scale to take uncertainty and convert it into risk. So, short-term economic uncertainty effectively kind of affects our cost of capital. And so, if it's more expensive for us to access capital to be able to pursue these things, we're going to be able to do less of them.”
“We're competing with China in certain sectors, particularly in biotechnology and we definitely are feeling the effects of that because they have a centrally planned economy that's focusing on some areas of relative advantage for them, particularly new drugs that can be developed very efficiently there and the US biotech industry is feeling that.”
“I think that the policies that we use in terms of funding basic research that leads to some of the major breakthroughs... There is a real battle going on as to whether that research is worth it and whether we should just get out of the business of funding scientific research by and large and that's really scary in my view.”
“So we are in the business officially at flagship at scale to take uncertainty and convert it into risk. So short-term economic uncertainty effectively kind of affects our cost of capital. And so if it's more expensive for us to access capital to be able to pursue these things, we're going to be able to do less of them. If we get more efficient with AI, we can do more with less.”
“We're competing with China in certain sectors, particularly in biotechnology, and we definitely are uh feeling the effects of that because they have a centrally planned economy that's focusing on some areas of relative advantage for them, particularly new drugs that can be developed very efficiently there and the US biotech industry is feeling that. These are things that are essentially not possible in the US. We're ”
“I'd say first and foremost our immigration policy has been a huge part of that in the sense that we've attracted the best and brightest from the world and we've been able to um incent them but to stay here and to contribute and that's been a very big driver. I think that the the policies that we use in terms of funding basic research that leads to some of the major breakthroughs... There is a real battle going on as ”
Sign in to search the full transcript archive, filter by topic, and access every quote from Noubar Afeyan.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans